ATE182792T1 - Wundheilung - Google Patents
WundheilungInfo
- Publication number
- ATE182792T1 ATE182792T1 AT92907214T AT92907214T ATE182792T1 AT E182792 T1 ATE182792 T1 AT E182792T1 AT 92907214 T AT92907214 T AT 92907214T AT 92907214 T AT92907214 T AT 92907214T AT E182792 T1 ATE182792 T1 AT E182792T1
- Authority
- AT
- Austria
- Prior art keywords
- composition
- disclosed
- wound healing
- wounds
- administering
- Prior art date
Links
- 230000029663 wound healing Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003102 growth factor Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 231100000241 scar Toxicity 0.000 abstract 1
- 230000009772 tissue formation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Transceivers (AREA)
- Mobile Radio Communication Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919106678A GB9106678D0 (en) | 1991-03-28 | 1991-03-28 | Wound healing |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE182792T1 true ATE182792T1 (de) | 1999-08-15 |
Family
ID=10692386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT92907214T ATE182792T1 (de) | 1991-03-28 | 1992-03-30 | Wundheilung |
Country Status (13)
Country | Link |
---|---|
US (4) | US5662904A (de) |
EP (1) | EP0585242B2 (de) |
JP (3) | JP3333507B2 (de) |
AT (1) | ATE182792T1 (de) |
AU (1) | AU661840B2 (de) |
CA (2) | CA2387247C (de) |
DE (1) | DE69229729T3 (de) |
DK (1) | DK0585242T4 (de) |
ES (1) | ES2136618T5 (de) |
GB (1) | GB9106678D0 (de) |
GR (1) | GR3030924T3 (de) |
IE (1) | IE921013A1 (de) |
WO (1) | WO1992017206A1 (de) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5654270A (en) | 1988-06-28 | 1997-08-05 | La Jolla Cancer Research Foundation | Use of fibromodulin to prevent or reduce dermal scarring |
US5571714A (en) * | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US5177197A (en) * | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
US6054122A (en) | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6117425A (en) | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
US7229959B1 (en) * | 1990-11-27 | 2007-06-12 | The American National Red Cross | Supplemented fibrin matrix delivery systems |
US6197325B1 (en) | 1990-11-27 | 2001-03-06 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
GB9106678D0 (en) * | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
AU673506B2 (en) * | 1991-11-14 | 1996-11-14 | La Jolla Cancer Research Foundation | Inhibitors of cell regulatory factors and methods for preventing or reducing scarring |
AU3609893A (en) * | 1992-01-29 | 1993-09-01 | La Jolla Cancer Research Foundation | Methods of controlling the proliferation of macrophages |
GB9205800D0 (en) * | 1992-03-17 | 1992-04-29 | British Tech Group | Treatment of fibrotic disorders |
GB9206861D0 (en) * | 1992-03-28 | 1992-05-13 | Univ Manchester | Wound healing and treatment of fibrotic disorders |
AU4769893A (en) * | 1992-07-17 | 1994-02-14 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
JPH08504763A (ja) * | 1992-10-29 | 1996-05-21 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | 治療薬としてのTGF−βレセプターフラグメントの使用 |
AU7053894A (en) * | 1993-06-09 | 1995-01-03 | Ribozyme Pharmaceuticals, Inc. | Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease |
WO1995000103A2 (en) * | 1993-06-15 | 1995-01-05 | Il-Yang Pharm. Co., Ltd. | Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof |
DE69434617D1 (de) * | 1993-11-19 | 2006-04-06 | Univ Sydney | Verfahren zur prophylaxe oder kontrolle des katarakts |
AU5698094A (en) * | 1993-12-09 | 1995-06-27 | Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh | Antisense nucleic acid for the treatment of diseases in which expression of bfgf, pdgf-a or pdgf-b plays a pathogenic role |
US5834440A (en) * | 1994-03-07 | 1998-11-10 | Immusol Incorporated | Ribozyme therapy for the inhibition of restenosis |
AU2099095A (en) * | 1994-03-07 | 1995-09-25 | Immusol, Inc | Ribozyme therapy for restenosis |
GB9405046D0 (en) * | 1994-03-15 | 1994-04-27 | Unilever Plc | Skin treatment composition |
GB2288118A (en) * | 1994-03-29 | 1995-10-11 | Univ Manchester | Wound healing composition |
JP4083794B2 (ja) * | 1994-03-29 | 2008-04-30 | レノボ・リミテッド | 創傷の治癒 |
US5824655A (en) * | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
GB2304045A (en) * | 1995-08-04 | 1997-03-12 | Univ Manchester | Betaglycan compositions for promoting the healing of wounds and fibrotic diseases |
GB2304047A (en) * | 1995-08-09 | 1997-03-12 | Univ Manchester | Pharmaceutical compositions containing cytokines |
GB9601081D0 (en) * | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
US7368111B2 (en) * | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
GB2306481A (en) * | 1995-10-21 | 1997-05-07 | Univ Manchester | Pharmaceutical comprising a stimulator of activin and/or inhibin |
GB9702943D0 (en) * | 1997-02-13 | 1997-04-02 | Univ Manchester | Wound healing |
AU9294698A (en) * | 1997-08-27 | 1999-03-16 | Beth Israel Deaconess Hospital Corp. | Methods and compositions for enhanced wound healing |
US6444657B1 (en) | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
WO2000051566A1 (en) * | 1999-03-04 | 2000-09-08 | United States Surgical Corporation | Scar reduction |
US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
US6630142B2 (en) | 1999-05-03 | 2003-10-07 | Zymogenetics, Inc. | Method of treating fibroproliferative disorders |
US7261881B1 (en) | 1999-05-20 | 2007-08-28 | Yale University | Modulation of angiogenesis and wound healing |
WO2001027264A1 (fr) * | 1999-10-15 | 2001-04-19 | Nihon University, School Juridical Person | Ribozymes agissant sur un facteur de croissance provenant des plaquettes humaines |
US6893637B1 (en) | 1999-10-21 | 2005-05-17 | Zymogenetics, Inc. | Method of treating fibrosis |
US20040197333A1 (en) * | 2000-02-10 | 2004-10-07 | Cornell Research Foundation, Inc. | Use of TGF-beta antagonists to inhibit tumor cell formation or progression |
WO2002030432A1 (en) * | 2000-06-23 | 2002-04-18 | Cambridgemed, Inc | Agent for reduction of scar formation by using wound alkalinization |
US6509318B1 (en) * | 2000-09-29 | 2003-01-21 | The Regents Of The University Of California | TGF-B inhibitors and methods |
AU2002227052A1 (en) | 2000-11-30 | 2002-06-11 | University Of Florida | Treatments for neurogenetic disorders, impulse control disorders, and wound healing |
US20040235791A1 (en) * | 2002-01-25 | 2004-11-25 | Gruskin Elliott A. | Scar reduction |
GB0217136D0 (en) | 2002-07-24 | 2002-09-04 | Renovo Ltd | Wound healing & treatment of fibrosis |
GB0309064D0 (en) | 2003-04-22 | 2003-05-28 | Univ Manchester | Modified peptides and their uses |
NZ546088A (en) | 2003-08-27 | 2009-10-30 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders using a PDGF antagonist and a VEGF antagonist |
AU2004293030A1 (en) * | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Electrical devices and anti-scarring agents |
JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック, インコーポレイテッド | ヒト化抗TGF−β抗体 |
DE102004025881A1 (de) * | 2004-05-19 | 2006-01-05 | Beiersdorf Ag | Oligoribonukleotide zur Beeinflussung des Haarwachstums |
US20070275874A1 (en) * | 2004-09-03 | 2007-11-29 | Yale University | Use of Leptin in Wound Healing |
US8109981B2 (en) | 2005-01-25 | 2012-02-07 | Valam Corporation | Optical therapies and devices |
WO2007048202A1 (en) * | 2005-10-25 | 2007-05-03 | Women's & Children's Health Research Institute | Methods and compositions for modulating wound repair |
US8353881B2 (en) | 2005-12-28 | 2013-01-15 | Abbott Diabetes Care Inc. | Infusion sets for the delivery of a therapeutic substance to a patient |
US7981034B2 (en) | 2006-02-28 | 2011-07-19 | Abbott Diabetes Care Inc. | Smart messages and alerts for an infusion delivery and management system |
US9119582B2 (en) | 2006-06-30 | 2015-09-01 | Abbott Diabetes Care, Inc. | Integrated analyte sensor and infusion device and methods therefor |
US8932216B2 (en) | 2006-08-07 | 2015-01-13 | Abbott Diabetes Care Inc. | Method and system for providing data management in integrated analyte monitoring and infusion system |
US8206296B2 (en) | 2006-08-07 | 2012-06-26 | Abbott Diabetes Care Inc. | Method and system for providing integrated analyte monitoring and infusion system therapy management |
US8641618B2 (en) | 2007-06-27 | 2014-02-04 | Abbott Diabetes Care Inc. | Method and structure for securing a monitoring device element |
US8085151B2 (en) | 2007-06-28 | 2011-12-27 | Abbott Diabetes Care Inc. | Signal converting cradle for medical condition monitoring and management system |
BRPI0914454A2 (pt) * | 2008-10-21 | 2015-10-27 | Novodermix Internat Ltd | "composição para o tratamento do tecido epitelial" |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP2401614A1 (de) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen |
US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
AU2014308751B2 (en) | 2013-08-22 | 2020-03-05 | Acceleron Pharma, Inc. | TGF-beta receptor type II variants and uses thereof |
EP3331550B1 (de) | 2015-08-04 | 2022-11-02 | Acceleron Pharma Inc. | Zusammensetzung zur behandlung von myeloproliferativen erkrankungen |
BR112019023071A2 (pt) | 2017-05-04 | 2020-06-09 | Acceleron Pharma Inc | proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5145676A (en) * | 1981-09-08 | 1992-09-08 | The Rockefeller University | Method and agents for promoting wound healing |
DE3382562D1 (de) * | 1982-09-24 | 1992-06-25 | Us Health | Wiederherstellung von gewebe bei tieren. |
US5104977A (en) * | 1982-09-24 | 1992-04-14 | The United States Of America As Represented By The Department Of Health And Human Services | Purified transforming growth factor beta |
WO1984004924A1 (en) * | 1983-06-03 | 1984-12-20 | Us Commerce | Purified transforming growth factor-beta derived from human platelets and placentas |
DE3629640A1 (de) * | 1986-08-30 | 1988-03-03 | Behringwerke Ag | Verwendung monoklonaler antikoerper zur therapie von tumoren |
US4708948A (en) * | 1984-04-20 | 1987-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Substantially purified tumor growth inhibitory factor |
DE3588058T3 (de) * | 1984-07-16 | 2005-04-07 | Celtrix Pharmaceuticals, Inc., Palo Alto | Knorpel-induzierende Polypeptid-Faktoren aus Knochen |
IL78197A (en) * | 1985-03-22 | 1991-07-18 | Genentech Inc | Nucleic acid encoding tgf-beta and its uses |
US5168051A (en) * | 1985-03-22 | 1992-12-01 | Genentech, Inc. | Nucleic acid encoding TGF-β its uses |
US4886747A (en) * | 1985-03-22 | 1989-12-12 | Genentech, Inc. | Nucleic acid encoding TGF-β and its uses |
IE60059B1 (en) * | 1985-04-19 | 1994-05-18 | Oncogene Science Inc | Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof |
US5262319A (en) * | 1985-04-19 | 1993-11-16 | Oncogene Science, Inc. | Method for obtaining bone marrow free of tumor cells using transforming growth factor β3 |
US4837381A (en) * | 1986-08-11 | 1989-06-06 | American Cyanamid Company | Compositions for parenteral administration and their use |
US4931548A (en) * | 1987-01-30 | 1990-06-05 | Techne Corporation | Heterodimer form of transforming growth factor-beta |
WO1988007057A1 (en) * | 1987-03-13 | 1988-09-22 | Amgen Inc. | Purified platelet-derived growth factor and methods for purification thereof |
EP0418234B1 (de) * | 1988-06-08 | 1994-03-23 | Genentech, Inc. | Nukleinsäure, die tgf-b3 kodiert, und ihre verwendung |
US5055447A (en) * | 1988-07-28 | 1991-10-08 | Genentech, Inc. | Method and compositions for the treatment and prevention of septic shock |
GB8823649D0 (en) * | 1988-10-07 | 1988-11-16 | Geistlich Soehne Ag | Chemical compounds |
US5135915A (en) * | 1988-10-14 | 1992-08-04 | Genentech, Inc. | Method for the treatment of grafts prior to transplantation using TGF-.beta. |
IE61346B1 (en) * | 1988-11-02 | 1994-11-02 | Genentech Inc | A permeable material to fit around the teeth or gums of a mammal |
CA2005120A1 (en) * | 1988-12-15 | 1990-06-15 | Anthony F. Purchio | Tgf-beta 1/beta 2: a novel chimeric transforming growth factor-beta |
US5061786A (en) * | 1989-05-25 | 1991-10-29 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
US5118791A (en) * | 1989-05-25 | 1992-06-02 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
DE69030956T2 (de) * | 1989-09-29 | 1998-01-15 | La Jolla Cancer Research Foundation, La Jolla, Calif. | Inhibierung des Transformierenden Wachstumsfaktors zur Verhinderung der Anhäufung Extrazellulärer Matrix |
GB8927546D0 (en) * | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
WO1991010727A1 (en) * | 1990-01-22 | 1991-07-25 | La Jolla Cancer Research Foundation | Inhibitors of cell regulatory factors |
US5147854A (en) * | 1990-05-22 | 1992-09-15 | Hoffmann-La Roche Inc. | Tgf-b compositions and method |
CA2084992A1 (en) * | 1990-06-25 | 1991-12-26 | Osi Pharmaceuticals, Inc. | Tissue-derived tumor growth inhibitors, methods for preparation and uses thereof |
US5149801A (en) * | 1990-11-21 | 1992-09-22 | The Regents Of The University Of California | Boronated porphyrin compounds |
GB9101645D0 (en) * | 1991-01-25 | 1991-03-06 | British Bio Technology | Compounds |
AU1426792A (en) * | 1991-02-04 | 1992-09-07 | Oncogene Science, Inc. | Inhibition of multidrug transport by transforming growth factor beta and uses thereof |
GB9106678D0 (en) * | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
CA2071137A1 (en) * | 1991-07-10 | 1993-01-11 | Clarence C. Lee | Composition and method for revitalizing scar tissue |
AU2738392A (en) * | 1991-11-11 | 1993-05-13 | Ciba-Geigy Ag | Novel hybrid transforming growth factors |
GB9205800D0 (en) * | 1992-03-17 | 1992-04-29 | British Tech Group | Treatment of fibrotic disorders |
GB9206861D0 (en) * | 1992-03-28 | 1992-05-13 | Univ Manchester | Wound healing and treatment of fibrotic disorders |
WO1995000103A2 (en) * | 1993-06-15 | 1995-01-05 | Il-Yang Pharm. Co., Ltd. | Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof |
JP4083794B2 (ja) * | 1994-03-29 | 2008-04-30 | レノボ・リミテッド | 創傷の治癒 |
-
1991
- 1991-03-28 GB GB919106678A patent/GB9106678D0/en active Pending
-
1992
- 1992-03-30 IE IE101392A patent/IE921013A1/en not_active IP Right Cessation
- 1992-03-30 DK DK92907214T patent/DK0585242T4/da active
- 1992-03-30 AT AT92907214T patent/ATE182792T1/de not_active IP Right Cessation
- 1992-03-30 DE DE69229729T patent/DE69229729T3/de not_active Expired - Lifetime
- 1992-03-30 US US08/122,508 patent/US5662904A/en not_active Expired - Lifetime
- 1992-03-30 AU AU14368/92A patent/AU661840B2/en not_active Ceased
- 1992-03-30 WO PCT/GB1992/000570 patent/WO1992017206A1/en active IP Right Grant
- 1992-03-30 EP EP92907214A patent/EP0585242B2/de not_active Expired - Lifetime
- 1992-03-30 CA CA002387247A patent/CA2387247C/en not_active Expired - Lifetime
- 1992-03-30 JP JP50694492A patent/JP3333507B2/ja not_active Expired - Fee Related
- 1992-03-30 CA CA002105652A patent/CA2105652C/en not_active Expired - Lifetime
- 1992-03-30 ES ES92907214T patent/ES2136618T5/es not_active Expired - Lifetime
-
1999
- 1999-08-05 GR GR990401862T patent/GR3030924T3/el unknown
-
2002
- 2002-02-06 JP JP2002029691A patent/JP2002275094A/ja active Pending
- 2002-04-08 US US10/117,351 patent/US20020187149A1/en not_active Abandoned
-
2005
- 2005-06-16 US US11/153,897 patent/US20050287139A1/en not_active Abandoned
- 2005-09-14 JP JP2005267284A patent/JP2006001949A/ja active Pending
-
2009
- 2009-06-08 US US12/457,346 patent/US20100152095A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU661840B2 (en) | 1995-08-10 |
DK0585242T3 (da) | 1999-12-06 |
EP0585242A1 (de) | 1994-03-09 |
ES2136618T5 (es) | 2007-10-16 |
US20050287139A1 (en) | 2005-12-29 |
ES2136618T3 (es) | 1999-12-01 |
GR3030924T3 (en) | 1999-11-30 |
JP3333507B2 (ja) | 2002-10-15 |
DE69229729D1 (de) | 1999-09-09 |
CA2105652A1 (en) | 1992-09-29 |
DK0585242T4 (da) | 2007-07-02 |
JP2002275094A (ja) | 2002-09-25 |
JPH06506205A (ja) | 1994-07-14 |
EP0585242B1 (de) | 1999-08-04 |
US5662904A (en) | 1997-09-02 |
US20020187149A1 (en) | 2002-12-12 |
EP0585242B2 (de) | 2007-03-07 |
JP2006001949A (ja) | 2006-01-05 |
GB9106678D0 (en) | 1991-05-15 |
CA2387247C (en) | 2009-05-19 |
WO1992017206A1 (en) | 1992-10-15 |
DE69229729T2 (de) | 2000-01-13 |
CA2387247A1 (en) | 1992-10-15 |
DE69229729T3 (de) | 2007-10-18 |
US20100152095A1 (en) | 2010-06-17 |
AU1436892A (en) | 1992-11-02 |
IE921013A1 (en) | 1992-10-07 |
CA2105652C (en) | 2005-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0585242T4 (da) | Sårheling | |
PT1009425E (pt) | Cicatrizacao de feridas | |
HK1046096A1 (en) | Solutions and methods for inhibitions of pain, inflammation and cartilage degradation | |
BR0014996A (pt) | Método para prevenir ou melhorar a dor de um ferimento fechado cirurgicamente em um indivìduo, e, emplastro | |
HU9402771D0 (en) | Pharmaceutical compositions for wound healing and treatment of fibrotic disorders | |
NO985575L (no) | FremgangsmÕter og preparater anvendelige for inhibering av <alfa>v<beta>5-mediert angiogenese | |
NZ331710A (en) | Regeneration of growth tissue in wound using an encasement, mechanical guide and thrombin inhibitor | |
DE59600683D1 (de) | Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten | |
CA2156481A1 (en) | 5-ht2 receptor antagonist compositions useful in treating venous conditions | |
ATE201598T1 (de) | Verwendung von moxonidin zur behandlung neuropathischer schmerzen | |
SE9101840L (sv) | Ny medicinsk anvaendning | |
EP0343807A3 (de) | Absorbierendes Heftpflaster mit kontrollierter Hydratierung | |
ATE297739T1 (de) | Endothelin-antagonisten zur behandlung von herzversagen | |
Ceilley et al. | Pinch grafting for chronic ulcers on lower extremities | |
MY126321A (en) | Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer. | |
CO5280202A1 (es) | Metodos de tratamiento y metodos de rastreo de farmacos | |
Stevenson et al. | The superficial inferior epigastric artery flap for coverage of hand and forearm defects | |
AU1345000A (en) | Irrigation solution and method for inhibition of pain and inflammation | |
CZ223199A3 (cs) | Použití inhibitorů COMT nebo jejich farmaceuticky vhodných solí nebo esterů pro výrobu léčiva k prevenci diabetických vaskulárních dysfunkcí | |
WO1997026880A3 (en) | Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients | |
MY118982A (en) | Method of reducing tissue damage associated with ischemia | |
ES2131331T3 (es) | Uso de benzotiofenos para la preparacion de un medicamento para reducir la formacion de cicatrices en la curacion de heridas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
EEIH | Change in the person of patent owner | ||
UEP | Publication of translation of european patent specification |
Ref document number: 0585242 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |